Original Article
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer
Article first published online: 12 JAN 2011
DOI: 10.1002/pros.21333
Copyright © 2011 Wiley-Liss, Inc.
Additional Information
How to Cite
Ghadersohi, A., Sharma, S., Zhang, S., Azrak, R. G., Wilding, G. E., Manjili, M. H. and Li, F. (2011), Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate, 71: 1178–1188. doi: 10.1002/pros.21333
Publication History
- Issue published online: 9 JUN 2011
- Article first published online: 12 JAN 2011
- Manuscript Accepted: 3 DEC 2010
- Manuscript Received: 16 SEP 2010
Funded by
- NIH. Grant Number: CA109481
- Susan Komen Foundation. Grant Number: BCTR63806
- American Cancer Society. Grant Number: IRG-02-197-06
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , PDEF in Prostate Cancer, The Prostate, 2012, 72, 6Direct Link:
- 2, , Prostate derived ETS factor (PDEF): A putative tumor metastasis suppressor, Cancer Letters, 2011, 310, 1, 109

1097-0045/asset/PROS_centre.gif?v=1&s=a32c0a233beb1a9c2871949185de4c172dac92bc)
